Skip to main content

August 2013, Vol 6 ADA 2013 Highlights

Intensive Treatment Early in Type 1 Diabetes Produces Substantial Long-Term Benefits

New Data Show Ranolazine Most Effective Antianginal Agent for Patients with Type 2 Diabetes and HbA1c >7%

Albiglutide, a GLP-1 Receptor Agonist, Effective in Various Treatment Scenarios in Patients with Type 2 Diabetes

Financial Incentives Can Promote Maintenance of Weight Loss, a Major Factor in Diabetes

Costs of Diabetes-Related Complications Reduced with Canagliflozin Monotherapy

Resource Utilization and Costs: Comparing Saxagliptin and Sitagliptin

Substantial Costs for Diabetes Are Consumed by the Diabetic Foot and Arthritis

Specialized Team Approach and Education Improve Care, Save Money in Diabetes

Future of Healthcare Reform: Expect New Payment and Delivery Models

Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes

Page 1 of 2
Results 1 - 10 of 19